13.96

3.73% 0.425

Relay Therapeutics Inc (RLAY)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RLAY? Forum Prognose

Schlusskurs vom Vortag:

$13.53

Offen:

$13.91

24-Stunden-Volumen:

1.31M

Relative Volume:

0.39

Marktkapitalisierung:

$3.00B

Einnahmen:

$15.36M

Nettoeinkommen (Verlust:

$-276.48M

KGV:

-8.6521

EPS:

-1.6129

Netto-Cashflow:

$-235.87M

1W Leistung:

+16.27%

1M Leistung:

-7.24%

6M Leistung:

+74.77%

1J Leistung:

+382.27%

1-Tages-Spanne:

$13.26

$14.08

1-Wochen-Bereich:

$11.62

$15.45

52-Wochen-Spanne:

$2.825

$17.32

Relay Therapeutics Inc Stock (RLAY) Company Profile

Firmenname

Relay Therapeutics Inc

Sektor

Healthcare (1110)

Branche

Biotechnology (618)

Telefon

617-370-8837

Adresse

60 HAMPSHIRE STREET, CAMBRIDGE

Mitarbeiter

192

Twitter

Nächster Verdiensttermin

2026-05-05

Neueste SEC-Einreichungen

RLAY's Discussions on Twitter

Compare RLAY vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RLAY Relay Therapeutics Inc	13.96	2.90B	15.36M	-276.48M	-235.87M	-1.6129
VRTX Vertex Pharmaceuticals Inc	436.69	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.91	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.47	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	294.95	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.71	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-26	Hochstufung	Oppenheimer	Perform → Outperform
2025-12-12	Hochstufung	Wells Fargo	Equal Weight → Overweight
2025-09-04	Fortgesetzt	Guggenheim	Buy
2025-04-17	Eingeleitet	Wells Fargo	Equal Weight
2024-09-10	Fortgesetzt	Goldman	Buy
2024-09-10	Hochstufung	Jefferies	Hold → Buy
2024-09-10	Herabstufung	Oppenheimer	Outperform → Perform
2024-05-10	Hochstufung	Barclays	Equal Weight → Overweight
2023-04-20	Hochstufung	Jefferies	Underperform → Hold
2023-04-19	Hochstufung	Raymond James	Outperform → Strong Buy
2023-04-13	Eingeleitet	Raymond James	Outperform
2023-02-03	Eingeleitet	Oppenheimer	Outperform
2022-09-30	Eingeleitet	Barclays	Equal Weight
2022-09-02	Eingeleitet	Stifel	Buy
2022-06-06	Eingeleitet	Jefferies	Underperform
2022-02-01	Eingeleitet	Berenberg	Buy
2021-07-21	Eingeleitet	BofA Securities	Buy
2020-12-15	Bestätigt	H.C. Wainwright	Buy
2020-12-08	Eingeleitet	JMP Securities	Mkt Outperform
2020-11-05	Eingeleitet	H.C. Wainwright	Buy
2020-08-10	Eingeleitet	Cowen	Outperform
2020-08-10	Eingeleitet	Goldman	Buy
2020-08-10	Eingeleitet	Guggenheim	Buy
2020-08-10	Eingeleitet	JP Morgan	Neutral

Alle ansehen

Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten

10:05 AM

RLAY Maintained by Guggenheim -- Price Target Raised to $26 - GuruFocus

10:05 AM

09:54 AM

RLAY stock declines pre-market after $175M offering — despite fresh bullish calls on Relay's zovegalisib - MSN

09:54 AM

08:14 AM

Guggenheim raises Relay Therapeutics stock price target on drug profile By Investing.com - Investing.com Australia

08:14 AM

08:07 AM

RLAY Maintained by HC Wainwright & Co. -- Price Target Raised to $28 - GuruFocus

08:07 AM

08:05 AM

H.C. Wainwright raises Relay Therapeutics stock price target to $28 on trial data - Investing.com Nigeria

08:05 AM

07:39 AM

Guggenheim Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $26 - Moomoo

07:39 AM

May 25, 2026

Relay Therapeutics shares jump after positive vascular anomalies trial results (RLAY) - MSN

May 25, 2026

RLAY stock lights up on vascular anomalies treatment data boost – 60% of patients show sharp reduction in lesion volume - MSN

May 25, 2026

May 24, 2026

Relay rises on mid-stage trial data for lead asset in vascular anomalies - MSN

May 24, 2026

RLAY Stock Declines Pre-Market After $175M Offering — Despite Fresh Bullish Calls On Relay's Zovegalisib - Stocktwits

May 24, 2026

May 22, 2026